A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
A phase 3 trial of Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, Capecitabine and Cisplatin in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, now recruiting.
Overview
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer is a phase 3 interventional study registered as NCT06764875 by AstraZeneca, with 840 participants planned, started 2025-03-01 and due to reach its primary completion in 2029-04-27. Interventions recorded: Rilvegostomig, Trastuzumab deruxtecan, Trastuzumab, Pembrolizumab, 5-fluorouracil and Capecitabine.
Similar pages
not linked directly; found by shared links- TrialNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Rilvegostomig, Capecitabine, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Rilvegostomig, Trastuzumab deruxtecan, Cisplatin, AstraZeneca and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Capecitabine, Trastuzumab, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Shares Rilvegostomig, Capecitabine, Trastuzumab, Trastuzumab deruxtecan and the tag pipeline.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Trastuzumab, Trastuzumab deruxtecan, Gastric & gastro-oesophageal junction cancer, Pembrolizumab and the tag pipeline.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Shares Rilvegostomig, AstraZeneca, Pembrolizumab and the tag pipeline.
- TrialRilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
- TrialSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Shares Rilvegostomig, Capecitabine, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.